Drugs / CAR-T CD19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04257175 | Feb 2020 → Dec 2024 | acute myeloid leukemia | Sheba Medical Center | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T CD19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04257175 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor (CAR-T) engineered T cells against the CD19 protein” NCT04257175 ↗ |
| Route | Intravenous | “The CAR-T infusion will be given in IV infusion.” NCT04257175 ↗ |
| Target | CD19 | “against the CD19 protein” NCT04257175 ↗ |